Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × elacestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 23 Advanced Breast Cancer 2 Sarcoma, Endometrial Stromal 1 Recurrence 1 Perivascular Epithelioid Cell Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Endometrial Neoplasms 1 ESR1 Gene Mutation 1 ER+ Breast Cancer 1 Central Nervous System Neoplasms 1 Central Nervous System Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Cancer Patients 1 Brain Neoplasms 1 Brain Diseases 1 Advanced ER+, HER2-Negative Breast Cancer 1 Adenosarcoma of the uterus 1

Interventions

pembrolizumab 155 Gemcitabine 140 Capecitabine 123 Paclitaxel 120 Fluorouracil 117 Oxaliplatin 110 Bevacizumab 106 Nivolumab 98 Leucovorin 97 Docetaxel 97 Cisplatin 89 Radiosurgery 88 Irinotecan 87 Carboplatin 85 Cetuximab 72 Cyclophosphamide 71 Magnetic Resonance Spectroscopy 67 Radiotherapy 60 Trastuzumab 59 Biopsy 59 Specimen Handling 58 Ipilimumab 51 Drug Therapy 51 Everolimus 48 Pemetrexed 45 Albumin-Bound Paclitaxel 45 130-nm albumin-bound paclitaxel 44 Doxorubicin 42 Fulvestrant 39 aldesleukin 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06201234 2025-12-01

ELEMENT

GBG Forschungs GmbH

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡